Baseline factors independently associated with a higher incidence of sustained visual acuity loss were the presence of nonfoveal GA ( odds ratio -LSB- OR -RSB- , @ ; @ % CI , @-@ @ ; P = @ ) , larger area of choroidal neovascularization ( OR for a > @-disc area vs @-disc area , @ ; @ % CI , @-@ @ ; P = @ ) , and bevacizumab treatment ( OR , @ ; @ % CI , @-@ @ ; P = @ ) .